Business
Turbine Secures $25M Series B Led by Interactive Venture Partners with participation from Beiersdorf Venture Capital, Announces First Immunology Partnership with Top 10 Pharma Company
Turbine, a leading virtual biology company, today announced a $25 million Series B financing, an expansion of its virtual cell platform across industries and a new immunology-focused partnership with a top 10 pharma company.
About this update from Beiersdorf Ag
[{"type":"text","content":"LONDON and BUDAPEST, Hungary, Feb. 24, 2026 /PRNewswire/ -- Turbine, a leading virtual biology company, today announced a $25 million Series B financing, an expansion of its virtual cell platform across industries and a new immunology-focused partnership with a top 10 pharma company.","length":284,"tagName":"p"},{"type":"image","alt":"Turbine Logo (PRNewsfoto/Turbine)","displaySize":"","headline":null,"caption":"Turbine Logo (PRNewsfoto/Turbine)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":188,"url":"https://media.zenfs.com/en/prnewswire.com/b7fa70696d7bf5431298809853dd780d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8oA7QeAbWv2mfk.pMbxlBQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMzMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b7fa70696d7bf5431298809853dd780d","width":400,"height":188}},"href":"https://mma.prnewswire.com/media/2728654/White_Turbine_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Series B round is led by Interactive Venture Partners, with participation from Beiersdorf AG and existing investors, including MSD Global Health Innovation, Accel and Mercia.","length":178,"tagName":"p","attribs":{}},{"type":"text","content":""Central and Eastern Europe has produced exceptional innovation, and Turbine stands out as one of the region's most compelling virtual biology platforms. Our team assessed the opportunity from both a technology and life sciences perspective, and we believe the ambitious team's unique capability to virtualize biological experiments with AI positions them to be among the global leaders embedding such technology into biopharma R&D," said Laszlo Czirjak, Managing Partner at Interactive VP, a fund backed by the family office of Thomas Peterffy, Founder and Chairman of Interactive Brokers Group, Inc.","length":628,"tagName":"p","attribs":{}},{"type":"text","content":"With the new funding, Turbine will expand its platform to virtualize new assays across discovery and translational medicine. Turbine's lab-in-the-loop will generate additional proprietary perturbation datasets, allowing the company to fine-tune its foundational virtual cell model to novel assay and tissue types. These virtual assays are deployed through the company's Virtual Lab, a no-code platform that integrates with pharm...